Search Results

Evotec SE announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that it has entered into a sponsored research agreement with Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome.

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm.

Cytovia Therapeutics, an emerging biopharmaceutical company, announces that it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting CD38, a key marker of multiple myeloma.

BioData has announced the roll-out of its Electronic Lab Notebook (ELN) platform, Labguru, with Inserm, France’s only public research institute to focus entirely on human health.

LinKinVax, a clinical-stage biotechnology company, welcomes the interim results of the ANRS VRI06 Phase I trial evaluating a preventive HIV vaccine and conducted by the sponsor INSERM-ANRS and the Vaccine Research Institute.

The global Artificial Intelligence company Expert System announced today that the French National Institute of Health and Medical Research, Inserm, has decided to implement its Clinical Research Navigator (CRN) tool and make it available to 100 of its researchers for an evaluation period of six months.

Collaboration with Professor Philippe Menasché (PARCC Cardiovascular Research Center - Inserm - Université Paris Cité - UMR 970 and Cardiovascular Surgery Department, Georges Pompidou European Hospital)